NCT04375085终止不适用
A Non-Randomized, Post Marketing Clinical Follow-Up (PMCF) Study of the DESyne X2 Novolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 49
- 试验地点
- 3
- 主要终点
- Acute Success
研究概览
简要总结
A single-arm post-market clinical follow-up study to confirm that the DESyne X2 delivery system performs similarly to the DESyne delivery system.
详细描述
A single-arm post-market follow up study (PMCF) comparing the DESyne X2 PMCF data to the historic DESyne acute performance data to confirm the performance of the DESyne X2 Novolimus Eluting Coronary Stent System with regards to the residual risks of lesion access and acute device implantation through visually-assessed angiographic endpoints and physician feedback.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient must be ≥ 18 years of age.
- •The patient must have stable angina pectoris as defined by the Canadian Cardiovascular Society Classification, documented silent ischemia, acute coronary syndrome, or a positive functional study requiring treatment
- •The patient is considered a candidate for coronary stent implantation and has a planned intervention of up to two lesions located in separate major epicardial territories. Each lesion/vessel must meet the following criteria:
- •De novo lesion
- •The target lesion reference site must be visually estimated to be ≥ 2.5 mm and ≤ 4.0 mm in diameter
- •The target vessel must be a major coronary artery or major branch with a visually estimated stenosis of ≥ 50% and < 100%.
- •The visually estimated target lesion length must be ≤ 34 mm
- •≥ TIMI 1 coronary flow
排除标准
- •The patient has a known hypersensitivity or contraindication to aspirin, heparin, ticlopidine, clopidogrel, prasugrel or ticagrelor, heparin/bivalirudin, mTOR inhibitor class drugs, cobalt chromium alloy, methacrylate or polylactide polymer, or sensitivity to contrast which cannot be adequately premedicated
- •Women of childbearing potential who have not undergone surgical sterilization or are not post-menopausal (defined as amenorrheic for at least one year) as well as women who are pregnant or nursing
- •Previous placement of a stent within 10 mm distal to the target lesion
- •Previous placement of a stent proximal to the target lesion
- •Total occlusion or < TIMI 1 coronary flow in the target vessel
- •The proximal target vessel or target lesion is severely calcified by visual assessment
- •Aorto-ostial location, unprotected left main lesion location, or a lesion within 5 mm of the origin of the left anterior descending or left circumflex
- •Lesion involvement of a significant side branch (branch diameter > 2 mm) that would be covered by stenting
- •High probability that treatment other than PTCA or stenting will be required for treatment of the same lesion
- •The target lesion, or the target vessel proximal to the target lesion, contains thrombus
- •The patient has suffered a myocardial infarction within the past 72 hours and the CK or CK-MB has not returned to normal at the time of the index procedure
- •The patient is a recipient of a heart transplant
- •The patient has extensive peripheral vascular disease that precludes safe sheath insertion or extreme anti-coagulation
- •The patient is currently participating in another investigational device or drug study that has not completed the primary follow-up phase
- •Patients who are unable or unwilling to cooperate with study procedures
结局指标
主要结局
Acute Success
时间窗: during procedure
attainment of final result with \< 50% residual stenosis of the target site, using a DESyne X2 stent and standard pre-dilation catheters and post-dilatation catheters (if applicable)
次要结局
- Physician Assessment Was Performed After Each Case(Post procedure)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
不适用
IRIS- DESyne X2 in the IRIS-DES RegistryCoronary StenosisCoronary OcclusionCoronary DiseaseNCT03588481Seung-Jung Park1,000
招募中
4 期
EASYII - A Post-Market Clinical Follow-up Study (PMCF) in patients with infrarenal aortic aneurysm undergoing endovascular stenting with the E-tegra Stent Graft System - imaging cohortNL-OMON55918JOTEC GmbH25
已完成
不适用
PMCF Study on the Safety, Performance and Clinical Benefits Data of the Zimmer® Plates and Screws SystemProximal Humeral FractureProximal Tibia FracturesDiaphyseal FractureNCT05215613Zimmer Biomet57
撤回
不适用
PMCF Study on the Safety, Performance and Clinical Benefits Data of the NexGen TM Augmentation PatellaNon-inflammatory Degenerative Joint DiseaseFunctional DeformityRevision Total Knee ArthroplastyRheumatoid ArthritisNCT05253976Zimmer Biomet
已完成
不适用
Post-Market Clinical Follow-up Study to endorse the performance and safety of Refluthin® chewable tablets in the rapid and lasting relief of heartburn and acid-related gastric discomfortR12HeartburnDRKS00029344Hälsa Pharma GmbH100